Scholarlink

<p>The spread of biofilm-forming multidrug-resistant pathogenic bacteria is an alarming public health issue requiring significant research. Drug repurposing is a novel approach to combating bacterial infections that is currently being studied. Here, we explored diclofenac sodium’s potential antibacterial and antibiofilm action on <i>Staphylococcus epidermidis</i> bacteria. Diclofenac sodium revealed antibacterial action on <i>S. epidermidis</i> isolates with minimum inhibitory concentrations of 500 to 2000&#xa0;µg/mL. It also exposed antibiofilm action using the crystal violet assay and scanning electron microscope. Using qRT-PCR, diclofenac sodium has downregulated the expression of the biofilm genes (<i>cna</i>, <i>fnb</i>A, and <i>ica</i>) in 20% of the isolates. An animal model revealed the effect of diclofenac sodium on a systemic infection with <i>S. epidermidis</i> in mice. Diclofenac sodium has improved the liver, spleen, and kidney architecture. Molecular docking was used to explore the possible mechanism for the activity of diclofenac sodium against <i>S. epidermidis</i>, which revealed the high affinity of diclofenac sodium toward <i>S. epidermidis</i> protein and TcaR enzymes. Thus, diclofenac sodium could be a clinical solution for disseminating resistance among <i>S. epidermidis</i> and could be investigated for its combination with different antibiotics in future studies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Employing diclofenac sodium as a novel therapeutic frontier for Staphylococcus epidermidis infections

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年8月26日

查看全文
  • Amal M. Abo-Kamar,
  • Ahmed A. Abdelaziz,
  • Alaa E. Ashour,
  • Moataz A. Shaldam,
  • Engy Elekhnawy

摘要

The spread of biofilm-forming multidrug-resistant pathogenic bacteria is an alarming public health issue requiring significant research. Drug repurposing is a novel approach to combating bacterial infections that is currently being studied. Here, we explored diclofenac sodium’s potential antibacterial and antibiofilm action on Staphylococcus epidermidis bacteria. Diclofenac sodium revealed antibacterial action on S. epidermidis isolates with minimum inhibitory concentrations of 500 to 2000 µg/mL. It also exposed antibiofilm action using the crystal violet assay and scanning electron microscope. Using qRT-PCR, diclofenac sodium has downregulated the expression of the biofilm genes (cna, fnbA, and ica) in 20% of the isolates. An animal model revealed the effect of diclofenac sodium on a systemic infection with S. epidermidis in mice. Diclofenac sodium has improved the liver, spleen, and kidney architecture. Molecular docking was used to explore the possible mechanism for the activity of diclofenac sodium against S. epidermidis, which revealed the high affinity of diclofenac sodium toward S. epidermidis protein and TcaR enzymes. Thus, diclofenac sodium could be a clinical solution for disseminating resistance among S. epidermidis and could be investigated for its combination with different antibiotics in future studies.